The number of drug companies that have signed “most favored nation” drug pricing deals with the Trump administration is set to expand on Friday.
The companies themselves have yet to be named, Endpoints Newsreported. However, the arrangements are expected to be fashioned similarly to those already done with Pfizer (PFE), Eli Lilly (LLY), Novo Nordisk (NVO), AstraZeneca (AZN), and EMD Serono (MKGAF).
Prior deals have involved offering some of a company’s drugs at sharply discounted rates for Medicare and Medicaid, and through the TrumpRx program in exchange for no tariffs on the companies for imported medications. For example, Lilly and Novo Nordisk are cutting prices of their GLP-1 treatments for weight loss.
The Trump administration previously sent letters to 17 pharmas telling them to lower prices. Among those who have yet to do so are Bristol Myers Squibb (BMY), Amgen (AMGN), Johnson & Johnson (JNJ), Merck (MRK), GSK (GSK), Gilead (GILD), Regeneron Pharmaceuticals (REGN), Novartis (NVS), Sanofi (SNY), and AbbVie (ABBV).
